Ramy Farid

Dr. Ramy Farid is President, Chief Executive Officer and a member of the board of directors of Schrödinger, Inc (NASDAQ: SDGR). He joined Schrödinger in 2002 and helped advance the company’s computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming CEO in 2017. Dr. Farid has played a key role in implementing major strategic initiatives, including more than 40 research collaborations and joint ventures, and led the company through its IPO in 2020. Dr. Farid currently serves on the board of directors of ShouTi. Previously, he served on the board of Nimbus Therapeutics, a biotechnology company he helped found in 2009. He also served on the board of directors of Morphic Therapeutic (NASDAQ: MORF) and currently serves on the company’s scientific advisory board. Dr. Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctorate degree in chemistry from Caltech. He is an author on 70 peer reviewed publications.